FedEx: Healthcare supply chains are becoming more complex
FedEx Corp. announced the launch of FedEx Life Sciences, a dedicated organisation created to support the increasingly complex movement of pharmaceuticals, medical devices, biologics, clinical trials, and other critical healthcare shipments.
As medicine becomes more specialized, global, and time-sensitive, life sciences companies need logistics networks built for precision, visibility, and reliability. From temperature-sensitive therapies and clinical trial materials to medical devices and patient-critical shipments, healthcare supply chains now require specialized support across highly regulated markets.
FedEx Life Sciences brings together the strength of the FedEx global network with a dedicated healthcare team and advanced monitoring capabilities to serve pharmaceutical and healthcare professionals working to deliver care to patients around the world.
As part of the launch, Nick Gennari will exclusively focus on this segment as president of healthcare and life sciences. Gennari joined FedEx in 1992 and has spent much of his more than 30-year tenure driving strategic sales and supply chain solutions for global healthcare, aerospace, and high-tech customers, before assuming leadership of the healthcare vertical in 2024. His appointment to lead this newly specialized organization reflects the FedEx commitment to pairing deep, long-standing sector expertise with its global logistics and technological capabilities. Gennari and his team’s efforts have been instrumental in growing FedEx healthcare revenue to approximately $10 billion globally.
“Healthcare depends on access, and access depends on certainty,” said Brie Carere, executive vice president and chief customer officer, FedEx. “Every shipment we move in this space has the potential to support a researcher, a physician, a clinician, a caregiver, or most importantly, a patient waiting for care. FedEx Life Sciences brings together our global network, advanced monitoring capabilities, and healthcare-focused expertise to help make supply chains smarter and more resilient. Under Nick’s leadership, this organization will help healthcare customers move with the speed, confidence, and precision patients require.”
FedEx Life Sciences builds on significant investments the company has made in healthcare infrastructure and technology. In 2025, FedEx secured IATA CEIV Pharma Corporate Certification, achieving corporate-level certification for ground handling across its air hubs and ramps. In addition, FedEx recently appointed a vice president of global quality, healthcare, and life sciences to oversee global quality management systems for the organization and support the standards required by pharmaceutical and medical device manufacturers.
FedEx has also expanded its life sciences footprint with a total of six Life Sciences Centers globally. Additionally, a direct flight between Indianapolis and Dublin has strengthened transatlantic connectivity between these two critical pharmaceutical manufacturing hubs, as the company continues to connect global pharmaceutical epicenters.
These assets are supported by FedEx Surround, a monitoring and intervention service that uses machine learning to provide proactive, end-to-end visibility for critical shipments, identify potential disruptions, and support intervention when timing, temperature, and reliability are essential.
“Healthcare supply chains are becoming more complex, and the stakes are deeply personal,” said Nick Gennari, president of healthcare and life sciences, FedEx. “FedEx Life Sciences gives our customers a more focused team, stronger coordination, and specialized expertise to help them move critical healthcare shipments with confidence. Our role is to provide the certainty, visibility, and global reach healthcare innovators need when every shipment matters.”
